InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,444.72
(
0.31%
)
Post# of 2341761
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

lucky__stock

Send PM Follow Ignore
Followers 0
Posts 7710
Boards Moderated 0
Alias Born 05/05/2020

lucky__stock

Re: lucky__stock post# 2276697

Friday, 03/04/2022 9:48:36 AM

Friday, March 04, 2022 9:48:36 AM

Post# of 2341761
$STAB On High Alert! Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19
Statera developing STAT-205 as novel therapy for immune modulation in treating post-acute (long-haul) patients with SARS-CoV-2 (COVID-19)

FORT COLLINS, Colo., March 02, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced submission to the U.S. Food and Drug Administration (FDA) of its pilot study protocol for STAT-205 treatment of post-acute (long-haul) COVID-19.

https://finance.yahoo.com/news/statera-biopharma-submits-phase-1-123000029.html
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up